Addison Advisors LLC Buys 395 Shares of GSK plc (NYSE:GSK)

Addison Advisors LLC grew its stake in GSK plc (NYSE:GSK) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,702 shares of the pharmaceutical company’s stock after acquiring an additional 395 shares during the period. Addison Advisors LLC’s holdings in GSK were worth $137,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Callahan Advisors LLC acquired a new position in GSK during the 3rd quarter worth $1,119,000. Horizon Bancorp Inc. IN lifted its stake in shares of GSK by 8.9% during the fourth quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after acquiring an additional 323 shares during the period. Cerity Partners LLC raised its holdings in GSK by 305.7% during the 4th quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after purchasing an additional 89,089 shares during the last quarter. Avantax Advisory Services Inc. raised its holdings in GSK by 23.6% during the 3rd quarter. Avantax Advisory Services Inc. now owns 76,840 shares of the pharmaceutical company’s stock worth $2,785,000 after purchasing an additional 14,689 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new position in GSK during the 4th quarter valued at about $7,024,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Up 0.5 %

GSK stock traded up $0.20 during mid-day trading on Friday, hitting $41.11. 2,730,464 shares of the company’s stock were exchanged, compared to its average volume of 2,904,690. The company’s 50 day simple moving average is $41.83 and its 200-day simple moving average is $38.95. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $85.20 billion, a P/E ratio of 13.66, a PEG ratio of 1.44 and a beta of 0.64. GSK plc has a fifty-two week low of $33.33 and a fifty-two week high of $43.84.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. On average, equities analysts anticipate that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were issued a $0.3564 dividend. This represents a $1.43 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend was Thursday, February 22nd. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio is 52.82%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent research reports. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Morgan Stanley initiated coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.